Understanding the Role of Amyloidosis in Heart Failure
Prevalence of Cardiac Amyloidosis in Patients With Hospitalization for Acute Heart Failure in the French West Indies
This study is trying to see how amyloidosis affects heart failure in people from the West Indies, especially looking for gene mutations in those showing signs of heart problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 446 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | University Hospital Center of Martinique Academic / other |
| Locations | 2 sites (Pointe-à-Pitre and 1 other locations) |
| Trial ID | NCT05501847 on ClinicalTrials.gov |
What this trial studies
This study investigates the relationship between cardiac amyloidosis and heart failure, particularly in the West Indian population. It focuses on patients exhibiting signs of acute heart failure and aims to identify the prevalence of transthyretin gene mutations that may contribute to this condition. The methodology includes clinical assessments and biomarker evaluations to confirm heart failure diagnosis. The study seeks to enhance understanding of this rare disease and its impact on heart function.
Who should consider this trial
Good fit: Ideal candidates are individuals showing functional signs of acute heart failure and confirmed by a cardiologist.
Not a fit: Patients without signs of heart failure or those under legal protection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and treatment strategies for heart failure related to amyloidosis, particularly in high-risk populations.
How similar studies have performed: While studies on heart failure are common, the specific focus on cardiac amyloidosis in the West Indian population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Present functional or physical signs of acute heart failure (exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, fatigue, jugular turgor, hepato-jugular reflux, edema of the lower limbs, galloping noise, crackles on pulmonary auscultation) * BNP \>100pg/mL or NT-proBNP \>300pg/mL * Diagnosis of heart failure confirmed by the cardiologist * Be affiliated to a social security plan or beneficiary * Be able to receive and understand information related to the research * Able to freely express his/her non-opposition or informed and written consent. Exclusion Criteria: * Person under legal protection (guardianship, curatorship, safeguard of justice), and person deprived of liberty.
Where this trial is running
Pointe-à-Pitre and 1 other locations
- Laurent LARIFLA — Pointe-à-Pitre, Guadeloupe (Not_yet_recruiting)
- CHU de Martinique — Fort-de-France, Martinique (Recruiting)
Study contacts
- Study coordinator: Jocelyne CRASPAG, MSc
- Email: jocelyne.craspag@chu-martinique.fr
- Phone: 0596592698
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.